Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Christopher Fraker
University of Miami School of Medicine, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ophysio
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Fraker holds an equity interest in Ophysio, a start-up company whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Optimizing encapsulation to treat Type 1 diabetes mellitus: the role of oxygenation, antigen shedding and innate immune response in graft success
PROJECT NARRATIVE This project aims at resolving long-standing problems in the encapsulation of insulin producing cells. As several groups are now on the verge of clinical translation of their production of insulin-producing cell aggregates, there is a clear need for the optimization of these delivery technologies. Through our proposed analysis of potential obstacles to engraftment of these tissues, it is our hope that we will co-develop, with our collaborators, a methodology for delivering these cellular products and optimizing their viability and function prior to clinical procedures. The public health impact of this research is a substantial reduction in the existing burden on the health care system that is imposed by treatment of Type 1 Diabetes Mellitus and the associated co-morbidities. If successful, the proposed work will lead to interventions that alleviate this burden and help the millions of patients worldwide afflicted with Type 1 Diabetes Mellitus. !
Filed on February 07, 2019.
Tell us what you know about Christopher Fraker's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Christopher Fraker”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Christopher Fraker | Ophysio, Inc. | Conflict of Interest | Ophysio, Inc. | Value cannot be readily determined |
| Christopher Fraker | Ophysio, Inc. | Conflict of Interest | Ophysio, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.